Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-7787 in Advanced Solid Tumors
NCT07268040Phase 2Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Bispecific Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of SHR-7787 in malignant solid tumor, sponsored by Hengrui Therapeutics. Started Dec 2025; status: recruiting.
02
Drugs
SHR-7787
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT07268040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07268040.